Artemisinin

Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis

Retrieved on: 
Tuesday, October 24, 2023
Ocean Biomedical, Disease, Artemisinin, Malaria, Doctor of Philosophy, Research, Pharmaceutical industry

Providence, RI, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates.

Key Points: 
  • Providence, RI, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Research Trust Transformational Award to advance a new class of anti-malarial drug candidates.
  • Dr. Kurtis’ malaria drug program stems from his groundbreaking malaria vaccine research , targeting a critical stage of the malaria cycle.
  • This program, which includes a therapeutic small molecule drug candidate for treating severe malaria, and a therapeutic antibody for short term malaria prevention, is designed to address the growing resistance to the current best-in-class Artemisinin-based medicines.
  • “It has become increasingly apparent that a new, more effective class of anti-malarials is needed, especially to combat severe malaria,” said Dr. Jonathan Kurtis, one of Ocean’s Scientific Co-Founders.

Locally transmitted malaria in the US could be a harbinger of rising disease risk in a warming climate – 5 questions answered

Retrieved on: 
Friday, June 30, 2023
RTS, Vaccine, Infection, BioNTech, Disease, Pfizer, Headache, Travel, Conversation, Florida International University, Parasitism, Climate, Convulsion, Chills, Breeding, Myalgia, R21, Fever, World, Plasmodium, Temperature, Medicine, Florida Department, Artemisinin, Centers for Disease Control and Prevention, Plasmodium knowlesi, CDC, Death, Vivax, Protein, Climate change, Primaquine, Patient, Risk, Water, Bill, Weather, Center, Prevention, Plasmodium vivax, Skin, Consciousness, Female, Fatigue, Insecticide, Pharmaceutical industry, Agriculture, Tea, Malaria, Anopheles

The Centers for Disease Control and Prevention reported on June 26, 2023, that five cases of locally transmitted malaria had been identified – four in Florida and one in Texas – since May 2023.

Key Points: 
  • The Centers for Disease Control and Prevention reported on June 26, 2023, that five cases of locally transmitted malaria had been identified – four in Florida and one in Texas – since May 2023.
  • These are the first cases of locally acquired mosquito-borne malaria in the U.S. since 2003.

1. What is malaria and how did these people become infected?

    • Malaria is a serious and sometimes life-threatening disease caused by the bite of a female mosquito from the genus Anopheles, the vector that transmits malaria.
    • The most common symptoms are fever, chills, headaches, muscle aches and fatigue.
    • These symptoms typically occur from 10 to 15 days after people are infected with the parasite.

2. Why might these cases be surfacing now?

    • For one, climate change is causing a shift in weather patterns, some of which can worsen malaria conditions.
    • A higher average surface temperature from global warming could lead to higher mosquito migration in areas that were previously uninhabitable by Anopheles mosquitoes.
    • Given these changes in local conditions, more cases could occur in populations that were previously “immunologically naïve” to malaria.
    • This drives up the number of drug-resistant cases, the severity of the illness and the possibility of larger outbreaks.

3. How can people help prevent malaria transmission?

    • Precautions also include what’s known as “drain and cover” – in other words, draining standing water to prevent mosquitoes from multiplying and using screens to prevent mosquitoes from entering through doors and windows.
    • Health departments also note that it’s important to drain or discard containers that can collect rainwater, such as flower pots, old tires and buckets.

4. What are the available malaria treatments?

    • There are several medicines used to prevent and treat malaria.
    • The choice of medication typically depends on the type of malaria, whether a malaria parasite is resistant to a medicine, the weight or age of the person infected with malaria and whether the person is pregnant.
    • These kill malaria parasites by damaging their proteins and are usually the most effective treatment against malaria.

5. Are vaccines against malaria available?

    • Therefore, in October 2021, the World Health Organization began recommending the widespread use of a malaria vaccine known as RTS,S/ASOI for children who live in moderate- to high-risk areas.
    • Trials show that the vaccine can significantly reduce malaria, including severe malaria, among young children.
    • While new malaria vaccines will be a major boost for curbing malaria worldwide, it will be critical for health departments to continue emphasizing other preventive strategies, especially in newly affected areas like Florida and Texas.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis

Retrieved on: 
Thursday, June 8, 2023
Vaccine, Executive, Partnership, Medical laboratory, Ocean Biomedical, Parasitism, Malaria, RI, Infection, Medicine, Research, Doctor of Philosophy, Fibrosis, Science, MD, Data, Pathology, Alpert Medical School, Parasitemia, Artemisinin, Death, IND, Family, Plasmodium falciparum, Pharmaceutical industry, Patent

Providence, RI, June 08, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD has been granted a new patent for his malaria vaccine discoveries that may be used to interdict the parasite at multiple stages in the malaria cycle. This extends patent protection for Dr. Kurtis’ novel discoveries that have defined the powerful roles of PfGARP and PfCDPK-5 in controlling the malaria parasite’s ability to aggressively multiply within its human host.

Key Points: 
  • This extends patent protection for Dr. Kurtis’ novel discoveries that have defined the powerful roles of PfGARP and PfCDPK-5 in controlling the malaria parasite’s ability to aggressively multiply within its human host.
  • This patent adds to Ocean Biomedical’s global patent portfolio for discoveries with potential to impact major unmet medical needs in infectious disease, oncology , and fibrosis .
  • Ocean Biomedical is working to optimize the formulation of this vaccine prior to IND submission and first-in-humans testing.
  • This medicine will be an additional focus of Ocean Biomedical’s development pipeline in 2023 and will address a massive unmet need.

Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis

Retrieved on: 
Tuesday, April 25, 2023
Vaccine, Goodwill, Monoclonal antibody, Therapy, Parasitism, Climate, PATH, Medical laboratory, RI, DC, Malaria, Research, Attention, ZERO, Doctor of Philosophy, Parliament, Pan-African Parliament, Death, Plasmodium falciparum, MD, Pathology, Brown University, SE, Artemisinin, Alpert Medical School, World Health Organization, Pharmaceutical industry, Southeast Asia, Ocean Biomedical

By targeting each of the three principle events in the parasite’s blood stage lifecycle, Ocean Biomedical believes this powerful approach will result in a highly effective and novel malaria vaccine.

Key Points: 
  • By targeting each of the three principle events in the parasite’s blood stage lifecycle, Ocean Biomedical believes this powerful approach will result in a highly effective and novel malaria vaccine.
  • The company is also working to develop the PfGARP component as a therapeutic target for a whole new class of anti-malarial drugs.
  • This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.
  • “I join the World Health Organization 2023 in saying, it is time for ZERO Malaria.”

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Developing “Whole New Class” of Malaria Therapeutics Issued to Scientific Co-founder Dr. Jonathan Kurtis

Retrieved on: 
Thursday, April 13, 2023
Patent, Ocean Biomedical, Cell death, Therapy, Parasitism, Climate, RI, United States Patent and Trademark Office, University, Season, Research, Doctor of Philosophy, Science, MD, Patient, Parasitemia, Artemisinin, Family, World Health Organization, Pharmaceutical industry, Vaccine, Malaria

A Notice of Allowance is issued after the USPTO examines a patent application and determines that the applicant should be granted a patent from the application.

Key Points: 
  • A Notice of Allowance is issued after the USPTO examines a patent application and determines that the applicant should be granted a patent from the application.
  • Ocean Biomedical anticipates that a patent will be issued by the USPTO from Dr. Kurtis’ application in the coming months.
  • “With the rising resistance to artemisinin-based drugs in sub-Saharan Africa, it is imperative that we get new malaria therapeutics into the drug development pipeline,” said Elizabeth Ng, Ocean Biomedical’s CEO.
  • This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.

Ocean Biomedical (NASDAQ: OCEA) Details Novel Malaria Therapeutic Discoveries at the NIH Laboratory of Malaria Vaccinology and Immunology on PfGARP’s Potential as a Highly Effective Vaccine Target and Therapeutic Candidate to Treat Malaria

Retrieved on: 
Tuesday, March 21, 2023
Drug development, Therapy, Parasitism, Climate, Medical laboratory, Kurtis, Ocean Biomedical, RI, CHI3L1, University, World Health Organization, DRS, Research, Doctor of Philosophy, Biology, Glioblastoma, Vaccine, Death, Science, MD, Pathology, Brown University, Parasitemia, Immunology, Artemisinin, Family, Alpert Medical School, NIH, Pharmaceutical industry, Medical device, Malaria, Medicine

Developments shared at the meeting detail how Dr. Kurtis’ team used a novel approach to capitalize on PfGARPs ability to kill parasites, targeting it for potential drug development.

Key Points: 
  • Developments shared at the meeting detail how Dr. Kurtis’ team used a novel approach to capitalize on PfGARPs ability to kill parasites, targeting it for potential drug development.
  • Dr. Elias is Ocean Biomedical’s other Scientific Co-founder and Dean Emeritus of Medicine and Biological Sciences at Brown University.
  • This differential screening technique has led to the discovery of three key targets that are being formulated into a highly effective malaria vaccine candidate being advanced by Dr. Kurtis and Ocean Biomedical.
  • This discovery has allowed Ocean Biomedical to begin simultaneously pursuing the development of a novel malaria vaccine, and novel malaria therapeutics.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Award of New Patent to Scientific Co-Founder Dr. Jake Kurtis for Novel Malaria Vaccine Target

Retrieved on: 
Tuesday, February 28, 2023
Medicine, Death, Parasitism, Maharashtra University of Health Sciences, Data, Malaria, Doctor of Philosophy, MD, Family, Pathology, Disease, Partnership, IND, Parasitemia, Research, Biological life cycle, Apoptosis, Patent, RI, Artemisinin, Human, Antibody, Medical laboratory, Ocean Biomedical, Vaccine, Pharmaceutical industry, Nature

Providence, RI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder and member of the board of directors Dr. Jonathan Kurtis, MD, PhD, has been awarded a new patent for his discovery related to malaria, a third parasite target called PfCDPK-5 that can potentially be used to interdict the parasite at multiple stages in the malaria cycle. This discovery builds on Dr. Kurtis’ previous discoveries that have defined the powerful roles of PfGARP and PfSEA in controlling the malaria parasite’s ability to replicate and grow within its human host. The latest patent is for the discovery that demonstrates the role of antibodies to PfCDPK-5 in preventing merozoites from escaping infected red blood cells and thus attenuates parasite multiplication in the bloodstream.

Key Points: 
  • If combined with the new target PfCDPK-5 and PfSEA, the vaccine has the potential to shut down the parasite at multiple points in its cycle.
  • In coming months, Dr. Kurtis will work to optimize the formulation of his vaccine prior to IND submission and first in humans testing.
  • This medicine will be an additional focus of Ocean Biomedical’s development pipeline in 2023 and will address a massive unmet need.
  • “Falciparum malaria is a leading cause of death in children world-wide and our global malaria treatment strategy relies almost exclusively on artemisinin-based drugs.

Novel Malaria Drug Discovery Presented at the ASTMH Tropical Medicine Meeting by Ocean Biomedical’s Scientific Co-founder, Dr. Jake Kurtis, unveiling the potential for a new class of Antimalarial Drugs.

Retrieved on: 
Tuesday, November 1, 2022
Growth, Ix, Apoptosis, Tropical medicine, SEC, GLOBE, Research, Antibody, COVID-19, Lung cancer, Attention, Human, Artemisinin, Brown University, Joint Medical Service (Germany), Brain, Investment, FDA, Pulmonary fibrosis, Madison Avenue, Failure, Risk, CEO, Transaction, Person, Suite, Safety, NASDAQ, Malaria, U.S. Securities and Exchange Commission, Patient, Medical laboratory, 100,000, Proxy, Therapy, Infection, Parasitism, RI, Parasitemia, Acquisition, Plasmodium, Nasdaq, University, Mergers and acquisitions, Communication, Death, SPAC, Tripura Merger Agreement, Pathology, Name, Society, Sale, Vaccine, XV, Probability, Hygiene, Forward-looking statement, Medical device, Pharmaceutical industry, Security (finance), Nature

Providence, RI and New York, NY, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today that Scientific Co-founder, Dr. Jake Kurtis, will present groundbreaking research discoveries at this week’s Annual Meeting of The American Society of Tropical Medicine and Hygiene. These discoveries have the potential to launch a whole new class of antimalarial drugs, and come at time when current artemisinin-based treatments are beginning to lose efficacy.

Key Points: 
  • Along with the related vaccine program, this small molecule drug program will be a key focus of Ocean Biomedicals development pipeline in 2023.
  • Malaria caused by infection with Plasmodium parasites is the greatest single-agent killer of children on the planet, killing approximately 627,000 individuals last year.
  • Suren Ajjarapu, Chairman and CEO of Aesther, commented, Aesther is honored to be part of the exciting discovery announced by Ocean Biomedical today.
  • Such information with respect to Ocean Biomedical's directors and executive officers will also be included in the proxy statement.

Building on Their Innovative mRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced Business Combination to Support the Discovery of a New Class of Antimalarial Drugs.

Retrieved on: 
Thursday, September 22, 2022
Safety, Artemisinin, Human, Transaction, 100,000, Medical laboratory, Parasitemia, Infection, Patient, Investment, U.S. Securities and Exchange Commission, NASDAQ, Research, Communication, Brain, Death, Risk, Probability, Tripura Merger Agreement, COVID-19, Suite, Mergers and acquisitions, Sale, Antibody, Acquisition, Growth, Malaria, Plasmodium, Person, Annual report, SPAC, Attention, SEC, Parasitism, Nasdaq, Failure, XV, Apoptosis, Ix, University, Joint Medical Service (Germany), FDA, RI, Forward-looking statement, CEO, Vaccine, Business architecture, Pathology, GLOBE, Proxy, Therapy, Pulmonary fibrosis, Name, Madison Avenue, Lung cancer, Program, Medical device, Pharmaceutical industry, Bank, Security (finance), Nature

Providence, RI and New York, NY, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) recently announced business combination, once closed, will further Ocean Biomedical’s work on the discovery of a whole new class of antimalarial drugs which target PfGARP and kill malaria parasites.

Key Points: 
  • Ocean Biomedical and Aesther Healthcare are proud to add this significant program to our pipeline.
  • Suren Ajjarapu, Chairman and CEO of Aesther, commented, Aesther is honored to be part of the exciting discovery announced by Ocean Biomedical today.
  • Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Ocean Biomedical.
  • Neither Ocean Biomedical nor Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations.

ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.

Retrieved on: 
Wednesday, December 22, 2021
Pancreatic cancer, Mutation, RNA, Genome, Entropy, Communication, Publication, Investigations into the origin of COVID-19, Patient, Private Securities Litigation Reform Act, Cancer, Cocaine, CEO, AML, Form 10-K, MedRxiv, Optimism, Acquisition, New, Serum, SEC, Survival, Therapy, Forward-looking statement, COVID-19, DIPG, Treatment, CA4P, Tree, Oxigen Services, Intelligence, Company, F120, Safety, Severe acute respiratory syndrome coronavirus 2, Annual report, CLIN, Risk, Melanoma, Radio spectrum, Glioma, GLOBE, Virology, Pharmaceutical industry, TGF, Omicron, Delta, Artemisinin, COVID

The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.

Key Points: 
  • The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.
  • ORF8 and the evolution of the Delta and Omicron variants.
  • Further mutations of these two residues are creating new lineage trees that are offshoots from the Delta backbone.
  • More importantly the further mutational expansion of the S-protein in the emerging Omicron variant is now followed with the acquisition of ORF8 mutations 119 and 120.